TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
$1,752,967
| Recipient | ABVIRO LLC UEI K3L6KXJ9B6M7 |
|---|---|
| Award ID | 75N93023C00055 |
| Award amount | $1,752,967 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AN12 |
| Start date | Sep 25, 2023 |
| End date | Jun 24, 2024 |
| Place of performance | BETHESDA, MD |
| Record updated | Oct 24, 2023 |
View the official award record
More awards won by ABVIRO LLC
IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.
Department of Health and Human Services · $29,431,752 · Sep 19, 2016
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids